Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth

Analyst Roanna Ruiz from Leerink Partners reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) and keeping the price target at $44.00.

Roanna Ruiz has given her Buy rating due to a combination of factors that highlight the potential of NewAmsterdam Pharma’s obicetrapib. The analysis conducted by Ruiz suggests that obicetrapib could significantly reduce major adverse cardiovascular events (MACE) by approximately 21%, with nearly half of this benefit potentially resulting from its strong ability to lower Lp(a) levels by about 45%. This differentiation in its profile positions obicetrapib as a promising candidate in the cardiovascular risk reduction market.
Moreover, Ruiz points out that obicetrapib’s potential benefits might extend beyond Lp(a) and LDL-C reduction, possibly affecting other lipids and reducing the onset of diabetes, although these were not the primary focus of the analysis. The drug’s multi-modal mechanisms of action and its convenient once-daily oral administration could provide it with a competitive edge over other lipid-lowering drugs under development. Ruiz’s analysis supports the view that obicetrapib could achieve peak revenues of around $3 billion in the US, reinforcing a positive outlook for NewAmsterdam Pharma’s stock leading up to 2026.

Ruiz covers the Healthcare sector, focusing on stocks such as Cytokinetics, Cormedix, and Lexicon Pharmaceuticals. According to TipRanks, Ruiz has an average return of -14.7% and a 29.82% success rate on recommended stocks.

In another report released on May 9, Scotiabank also maintained a Buy rating on the stock with a $52.00 price target.